What are the reconstitution instructions for GLOW peptide, which includes BPC-157 (Body Protection Compound 157), TB-500 (Thymosin Beta-4), and GHK-Cu (Copper-Glycine-Histidine-Lysine).

Reconstitution Instructions for GLOW Peptide

These instructions are for reconstituting GLOW Peptide Blend with BAC Water. This is strictly for laboratory use only and not intended for human use. This compound is not FDA Approved.

GLOW (research peptide blend)

GLOW is a research-use peptide blend that combines GHK-Cu, TB-500 (a Thymosin Beta-4 fragment), and BPC-157 in a single formulation.

GLOW is intended to target multiple regenerative mechanisms at once, with the goal of supporting a broader repair response than any one peptide might provide on its own.

Scope / Assumptions

• This protocol is specifically for a vial containing 70 mg of lyophilized peptide.
• Reconstitution volume used here: 3.0 mL bacteriostatic water (BAC water).

Materials

• Bacteriostatic water (BAC water): sterile diluent for multi-dose reconstitution
• 18G needle: for drawing BAC water / reconstituting the vial
• 30G insulin needle (U-100): for subcutaneous injection
• Alcohol prep pads: disinfect vial tops + injection site

Reconstitution (70 mg vial)

• Add 3.0 mL BAC water to 70 mg lyophilized peptide
• Final concentration: 70 mg / 3.0 mL = ~23.3 mg/mL

Dosing (example)

• Typical daily dose: 2,330 mcg (2.33 mg) once daily for 4 weeks
• U-100 insulin syringe math (at 23.3 mg/mL):
  • 1 unit = 0.01 mL ≈ 233 mcg
  • 10 units ≈ 2,330 mcg (2.33 mg)

Storage

• Before reconstitution (lyophilized): freeze at −20°C (−4°F)
• After reconstitution: refrigerate at 2–8°C (35.6–46.4°F), protect from light
• Use within: 4 weeks

Steps

1. Draw 3.0 mL BAC water using a sterile syringe.
2. Inject slowly down the vial wall to minimize foaming.
3. Gently swirl/roll until fully dissolved (do not shake vigorously).
4. Label the vial with the reconstitution date.
5. Refrigerate at 2–8°C, protected from light.
6. Use within 4 weeks for best potency/safety.

Important considerations

Storage after reconstitution

• Either use the reconstituted solution right away or store it exactly as the product labeling specifies (including the required temperature range).
• Verify the stability period after mixing (how long the reconstituted solution remains within spec).

Pitfalls to avoid

• Vigorous shaking: can cause heavy foaming and may denature the protein/peptide.
• Wrong diluent amount: adding too much or too little bacteriostatic water changes the final concentration.
• Incomplete dissolution: ensure the powder is fully dissolved before use so dosing is accurate.
• Contamination: keep sterile technique throughout the entire reconstitution process.

Regulatory and Safety Concerns

• BPC-157 is not FDA-approved and is currently banned by the World Anti-Doping Agency for use in professional sports, with significant concerns about unregulated manufacturing, potential contamination, and unknown clinical safety profiles 1.

• No pharmaceutical-grade standards exist for these compounds when sourced from compounding pharmacies, meaning there are no validated reconstitution protocols, sterility requirements, or quality control measures 1.

• TB-500 products have been identified as containing variable peptide fragments rather than full thymosin beta-4, with the actual composition being the N-terminal acetylated 17-23 fragment (Ac-LKKTETQ), raising concerns about product consistency and labeling accuracy 2.

Absence of Clinical Guidelines

• No medical guidelines exist from any major medical society (AAOS, ACSM, FDA, or other regulatory bodies) regarding the preparation, reconstitution, dosing, or administration of these peptides for clinical use.

• All published human studies used pre-prepared formulations by research teams or compounding pharmacies, not patient-level reconstitution instructions 3, 4.

• The only human safety data available is from a pilot study using pre-mixed BPC-157 in normal saline (10-20 mg in 250 cc) prepared by researchers, not end-users 3.

Clinical and Legal Liability

• Contamination risks are substantial when reconstituting peptides outside of sterile pharmaceutical environments, potentially leading to serious infections or adverse reactions.

• No established safety data exists for the combination product "GLOW peptide" specifically, and combining multiple peptides may create unpredictable interactions or stability issues.

What You Should Know

If you are considering using these peptides despite the above warnings:

• Consult with a licensed physician who can assess your specific medical situation and discuss the risks versus potential benefits of using investigational compounds 1.

• Only use products from 503A or 503B compounding pharmacies that follow USP <797> sterile compounding standards, though even these lack FDA oversight for these specific compounds 4.

• Understand that any use is experimental with unknown long-term safety profiles, no standardized dosing, and potential for serious adverse effects from contaminated or improperly prepared products 1.

• Be aware of the legal implications if you are subject to drug testing in athletic competitions or certain employment situations 1, 2.